Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS. Prebet T, et al. Among authors: ketterling r. J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24. J Clin Oncol. 2014. PMID: 24663049 Free PMC article. Clinical Trial.
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients.
Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, Litzow M, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Li M, et al. Among authors: ketterling r. Blood Adv. 2021 Apr 27;5(8):2272-2278. doi: 10.1182/bloodadvances.2020003976. Blood Adv. 2021. PMID: 33904893 Free PMC article. No abstract available.
Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.
Xie Z, Campestri G, Lasho T, Finke C, Li M, Binder M, Fernandez J, Olteanu H, Reichard KK, Ketterling R, Litzow M, Tefferi A, Mangaonkar A, Gangat N, Al-Kali A, Patnaik MM. Xie Z, et al. Among authors: ketterling r. Leuk Res. 2022 May;116:106818. doi: 10.1016/j.leukres.2022.106818. Epub 2022 Feb 22. Leuk Res. 2022. PMID: 35232597 No abstract available.
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.
Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Abdallah N, et al. Among authors: ketterling r. Clin Cancer Res. 2020 Dec 15;26(24):6581-6588. doi: 10.1158/1078-0432.CCR-20-2283. Epub 2020 Oct 2. Clin Cancer Res. 2020. PMID: 33008815 Free PMC article.
SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival.
Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. Wudhikarn K, et al. Among authors: ketterling r. Blood Adv. 2020 Nov 24;4(22):5716-5721. doi: 10.1182/bloodadvances.2020003345. Blood Adv. 2020. PMID: 33216886 Free PMC article. No abstract available.
455 results